Key Points
- Bicara Therapeutics CFO Ivan Hyep sold 9,200 shares on May 21 at an average price of $20.42, totaling about $187,864. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the transaction, Hyep still directly owned 145,355 shares valued at roughly $2.97 million, though his stake fell by 5.95%. He has also made several other recent sales of BCAX stock.
- BCAX shares were trading around $21.98, up 1.4% on the day, while the company recently reported a wider-than-expected quarterly loss of $0.93 per share versus estimates of a $0.72 loss. Analyst sentiment remains mixed but leans positive, with a consensus rating of Moderate Buy and an average target price of $30.27.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $20.42, for a total transaction of $187,864.00. Following the sale, the chief financial officer directly owned 145,355 shares of the company's stock, valued at $2,968,149.10. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ivan Hyep also recently made the following trade(s):
- On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.00, for a total transaction of $211,600.00.
- On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.52, for a total transaction of $170,384.00.
- On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75.
- On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10.
Bicara Therapeutics Trading Up 1.4%
Shares of Bicara Therapeutics stock opened at $21.98 on Wednesday. The company has a fifty day moving average price of $21.23 and a 200 day moving average price of $18.45. Bicara Therapeutics Inc. has a twelve month low of $8.48 and a twelve month high of $24.25. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -7.91 and a beta of -0.57.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.21). Analysts forecast that Bicara Therapeutics Inc. will post -3.37 earnings per share for the current year.
Hedge Funds Weigh In On Bicara Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after buying an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics in the 4th quarter worth $45,000. Larson Financial Group LLC lifted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after buying an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock worth $97,000 after buying an additional 4,585 shares in the last quarter.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on BCAX shares. Wall Street Zen raised shares of Bicara Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday. Citizens Jmp reaffirmed a "market outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. The Goldman Sachs Group upped their price target on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Tuesday, May 12th. HC Wainwright upped their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Finally, Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bicara Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $30.27.
Check Out Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
